廣告
香港股市 已收市
  • 恒指

    16,541.42
    +148.58 (+0.91%)
     
  • 國指

    5,810.79
    +82.66 (+1.44%)
     
  • 上證綜指

    3,041.17
    +30.50 (+1.01%)
     
  • 滬深300

    3,537.48
    +16.52 (+0.47%)
     
  • 美元

    7.8255
    -0.0001 (-0.00%)
     
  • 人民幣

    0.9221
    -0.0007 (-0.08%)
     
  • 道指

    39,807.37
    +47.29 (+0.12%)
     
  • 標普 500

    5,254.35
    +5.86 (+0.11%)
     
  • 納指

    16,379.46
    -20.06 (-0.12%)
     
  • 日圓

    0.0515
    +0.0001 (+0.10%)
     
  • 歐元

    8.4427
    +0.0021 (+0.02%)
     
  • 英鎊

    9.8860
    +0.0100 (+0.10%)
     
  • 紐約期油

    83.11
    -0.06 (-0.07%)
     
  • 金價

    2,254.80
    +16.40 (+0.73%)
     
  • Bitcoin

    69,466.82
    -1,921.98 (-2.69%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     

Impel NeuroPharma To Raise $45M Via Equity Offering

  • Impel NeuroPharma Inc's (NASDAQ: IMPL) has priced its previously announced underwritten public offering of 3 million shares at .00 per share for gross proceeds of $45 million.

  • The offer price represents a steep discount of 29% from the last close price of $21.13 on Thursday. The company's stock gained 27.25% to close higher on Thursday at $21.13.

  • See the offer prospectus here.

  • Underwriters have an option to purchase 0.45 million shares. The offering will close by September 14.

  • Impel will use the proceeds to fund the commercial launch activities and market development of Trudhesa, advance INP105 into a clinical proof-of-concept trial in patients with ASD.

  • Related Content: FDA Gives Nod To Nasal Spray Migraine Treatment From Impel NeuroPharma.

  • Read Next: Cowen Sees 100% Upside For This Medical Device Firm.

  • Price Action: IMPL stock is down 12.92% at $18.40 during the premarket session on the last check Friday.

See more from Benzinga

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.